Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

BEIJING, July 22, 2024 /PRNewswire/ -- Recently, Gan & Lee Pharmaceuticals(Gan & Lee, Shanghai Stock Exchange: 603087) announced that its independently developed long-acting GLP-1 receptor agonist (GLP-1 RA), GZR18 injection, has achieved positive results in a clinical trial for adults with obesity/overweight in China.

Statement:

1. GZR18 injection is an investigational drug and has not yet been approved in China.

2. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications.

The phase IIb clinical trial (CTR20231695) is a multi-center, randomized, double-blind, placebo-controlled study conducted at 25 clinical trial centers in China, recruiting a total of 340 participants. The participants were overweight (BMI≥24 kg/m²) with at least one weight-related comorbidity or obese (BMI≥28 kg/m²) adults with poorly controlled diet and exercise. They were randomized to receive bi-weekly (Q2W) doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly (QW) dose of 24 mg GZR18 injection or placebo for 30 weeks (including a dose escalation period). The primary efficacy endpoint of the study was the percent change in body weight from baseline after 30 weeks of treatment. The study assessed changes from baseline in average weight, waist circumference, waist-to-hip ratio, body mass index (BMI), glycemic parameters, and the safety and tolerability of the drug.

After 30 weeks of treatment, compared to the placebo group, participants receiving different doses and frequencies of GZR18 injection (12 mg, 18 mg, 24 mg, and 48 mg Q2W; 24 mg QW) had a significant reduction in the percent change in body weight from baseline. The mean percent changes in body weight from baseline was -11.15% (12 mg group, Q2W), -13.22% (18 mg group, Q2W), -14.25% (24 mg group, Q2W), -17.29% (48 mg group, Q2W), and -17.78% (24 mg group, QW), all more effective than the placebo group (reduced by 0.99%). There was no significant difference in mean percent change in body weight between the 48 mg Q2W group and the 24 mg QW group (one-sided test, P > 0.025).

In this study, the bi-weekly GZR18 injections were generally safe and well tolerated, consistent with the known safety signals of GLP-1 receptor agonists. The most common adverse events were gastrointestinal reactions, most of which were mild to moderate in severity, comparable to other GLP-1 RAs.

The comprehensive results of this phase IIb study are planned to be announced later this year and will be published in a peer-reviewed journal.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^â„¢), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^â„¢25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first among domestic companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.

Further Information:
BPRD@ganlee.com (Media)
BD@ganlee.com (Business Development)

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

DUBAI, UAE, Oct. 18, 2024 /PRNewswire/ -- During GITEX GLOBAL 2024, Huawei signed a strategic cooperation agreement with Alinma Bank to accelerate the digital transformation in the financial industry.

Alinma Bank, a Saudi Arabian epicenter for dynamic, innovative, Shariah-compliant banking and financial services, has partnered with Huawei for several years. This new agreement marks a major step forward in their cooperation.

Jason Cao, CEO of Digital Finance BU, Huawei, emphasized the robust relationship between Huawei and Alinma Bank. He said, "Alinma Bank is a leading bank in the Middle East with a great vision. Huawei looks forward to expanding the partnership to support Alinma Bank's digital transformation success with our technology, solutions and global experiences."

Trevor Liu, CEO of Huawei Saudi Rep. Office, underlined, "Huawei Saudi Office will go all out to support Alinma Bank with our best expertise in the team. We expect to gain a deeper understanding of the needs of Alinma Bank and provide the most suitable solutions and services to accelerate the digital transformation of Alinma Bank."

Yasser Aloufi, Chief Information Officer of Alinma Bank, said, "Huawei is our strategic partner. Since the cooperation started several years ago in IT infrastructure, we have been very satisfied with Huawei's performance. We are looking forward to deepening the cooperation with Huawei, which could expand from infrastructure to cloud solutions, and further evolve into a digital transformation partnership."

Huawei leverages leading innovative technologies and draws on its extensive expertise to help customers succeed through open collaboration with financial institutions and ecosystem partners, always looking for new ways to create value for our customers. By the end of September 2024, Huawei had served over 3,700 financial customers in more than 80 countries and regions, including 53 of the world's top 100 banks. Huawei had also established strategic partnerships with more than 80 large banks, insurers, and securities companies across the globe, becoming their trusted partner in digital transformation.

For more details, please visit: https://e.huawei.com/en/industries/finance 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Huawei and Alinma Bank Establish Strategic Partnership at GITEX GLOBAL 2024